West Nile virus (WNV) is a flavivirus and NIAID Category B infectious agent that is neurotropic and causes severe encephalitis, encephalopathy, and paralysis in humans and other animals. WNV has recently emerged into the Western hemisphere and now presents a serious worldwide public health threat. WNV and other members of the flavivirus family are arboviruses and present a biothreat through their ability to disseminate, via insect vector, throughout human population centers. Importantly, pathogenic WNV shares features of host immune defense evasion with other pathogenic members of the flavivirus family, therefore serving as a platform of study to define the virus-host interactions that control WNV/flavivirus infection. Our preliminary studies have revealed that cell tropism of WNV infection, and infection outcome, are in large part controlled by the host innate immune response and the actions of type 1 interferon (IFN) that are induced during infection. We have found that WNV and other flaviviruses trigger innate antiviral immune defenses through specific pathways of pathogen recognition within infected tissues and cells, and that the resulting IFN response triggered by these pathways differs among cells to restrict the tropism of infection. Our studies show that pathogenic WNV evades innate IFN defenses by disrupting IFN signaling, suggesting that ability to suppress the host IFN response forms the basis of neurovirulence and pathogenesis among strains. Our observations define the innate host response and virus countermeasures of IFN action as key determinants controlling immunity and pathogenesis of WNV infection. We hypothesize that viral triggering and control of the host response and IFN effector actions defines the cell tropism, virulence, and outcome of WNV infection. To investigate this hypothesis, we have designed collaborative studies that embrace the strengths of the Pacific Northwest Research Center of Excellence in Biodefense. As sub-project 1 of this programproject (P01) application, we will 1) Define the cell-specific pathogen recognition pathways that induce IFN and innate defenses against WNV infection, 2) Define the IFN-stimulated effector genes that control WNV infection, tropism and spread, and 3) Determine the molecular mechanisms by which pathogenic WNV antagonizes the host cell IFN response. These studies will integrate with P01 sub-projects 2 and 3 to determine how the host kinome and flavivirus inhibitor compounds interact with host innate immune programs to control WNV and flavivirus infection. Our work will deliver new therapeutic targets and therapy applications for the treatment of WNV and flavivirus infections.

Public Health Relevance

Our investigations will utilize virologic, immunologic, biochemical, and genetic/genomic approaches within in vitro and in vivo studies to define the virus/host interface of WNV infection that controls infection outcome, and will provide novel insights to guide therapeutic and vaccine strategies aimed at modulating immunity to infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI081680-05
Application #
8436324
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
5
Fiscal Year
2013
Total Cost
$515,591
Indirect Cost
$89,126
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Smith, Jessica L; Stein, David A; Shum, David et al. (2014) Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling. J Virol 88:5533-42
Trobaugh, Derek W; Gardner, Christina L; Sun, Chengqun et al. (2014) RNA viruses can hijack vertebrate microRNAs to suppress innate immunity. Nature 506:245-8
Haick, Anoria K; Rzepka, Joanna P; Brandon, Elizabeth et al. (2014) Neutrophils are needed for an effective immune response against pulmonary rat coronavirus infection, but also contribute to pathology. J Gen Virol 95:578-90
Gibbs, David L; Gralinski, Lisa; Baric, Ralph S et al. (2014) Multi-omic network signatures of disease. Front Genet 4:309
Gardner, Christina L; Hritz, Jozef; Sun, Chengqun et al. (2014) Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719
Josset, Laurence; Tchitchek, Nicolas; Gralinski, Lisa E et al. (2014) Annotation of long non-coding RNAs expressed in collaborative cross founder mice in response to respiratory virus infection reveals a new class of interferon-stimulated transcripts. RNA Biol 11:875-90
Nikolich-┼Żugich, Janko (2014) Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol 193:2622-9
Engelmann, Flora; Josset, Laurence; Girke, Thomas et al. (2014) Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl Trop Dis 8:e3295
Pal, Pankaj; Fox, Julie M; Hawman, David W et al. (2014) Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 88:8213-26
Fontaine, Krystal A; Camarda, Roman; Lagunoff, Michael (2014) Vaccinia virus requires glutamine but not glucose for efficient replication. J Virol 88:4366-74

Showing the most recent 10 out of 75 publications